Albany, NY -- (SBWIRE) -- 10/11/2019 -- Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology and Market Forecast-2028
1. Chronic Obstructive Pulmonary Disease is the third leading cause of death in the United States.
2. Approximately one in five people in the UK develop asthma, Chronic Obstructive Pulmonary Disease or another long-term respiratory illness.
3. Chronic Obstructive Pulmonary Disease to be the fourth most prevalent cause of death by 2030 after ischemic heart disease, cerebrovascular disease, and HIV/AIDS.
(Albany, US) DelveInsight launched a new report on Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Chronic Obstructive Pulmonary Disease market report covers a descriptive overview and comprehensive insight of the Chronic Obstructive Pulmonary Disease epidemiology and Chronic Obstructive Pulmonary Disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Chronic Obstructive Pulmonary Disease market report provides insights on the current and emerging therapies.
3. Chronic Obstructive Pulmonary Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Chronic Obstructive Pulmonary Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Obstructive Pulmonary Disease market.
Request for sample pages
"Approximately 3 million deaths occurred due to Chronic Obstructive Pulmonary Disease in 2015. The prevalence of Chronic Obstructive Pulmonary Disease is increasing with increasing age."
The goal of Chronic Obstructive Pulmonary Disease management is to improve a patient's functional status and quality of life by preserving optimal lung function, improving symptoms, and preventing the recurrence of exacerbations. There is currently no cure for chronic obstructive pulmonary disease, but Chronic Obstructive Pulmonary Disease treatment can help slow the progression of the condition and control the symptoms.
The most essential step in any Chronic Obstructive Pulmonary Disease treatment plan is to stop smoking (Smoking cessation).
Bronchodilators are the only therapeutic options which are effective against Chronic Obstructive Pulmonary Disease. These usually come in an inhaler and relax the muscles around your airways, which further helps in relieving coughing and shortness of breath. Depending on the severity of the disease, the use of a short-acting bronchodilator before activities or a long-acting bronchodilator or even both can be recommended.
Long-term oxygen therapy may be prescribed for patients with severe resting or patients with more moderate hypoxemia (and signs of heart failure, pulmonary hypertension, or polycythemia associated with Chronic Obstructive Pulmonary Disease. Lung transplantation in very severe cases has been shown to significantly improve lung function or decrease mortality.
The current market only offers a few approved therapies for Chronic Obstructive Pulmonary Disease treatment. Therefore, the launch of upcoming therapies will contribute to the overall growth of the Chronic Obstructive Pulmonary Disease market during the forecast period of 2019–2028.
The launch of the emerging therapies is expected to significantly impact Chronic Obstructive Pulmonary Disease treatment scenario in the upcoming years:-
Drugs covered
1. MV130
2. Dupilumab
3. Abediterol
4. DS102
And many others
The key players in Chronic Obstructive Pulmonary Disease market are:
1. Afimmune
2. Inmunotek S.L.
3. Sanofi
4. AstraZeneca
5. Pulmotect
And many others
Table of contents
1. Key Insights
2. Chronic Obstructive Pulmonary Disease Market Overview at a Glance
3. Chronic Obstructive Pulmonary Disease Disease Background and Overview
4. Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population
5. Chronic Obstructive Pulmonary Disease Prevalent cases
6. C Chronic Obstructive Pulmonary Disease country Wise-Epidemiology
6.1. United States
6.2. EU5 Countries
6.2.1. Germany
6.2.2. France
6.2.3. Italy
6.2.4. Spain
6.2.5. United Kingdom
6.3. Japan
7. Chronic Obstructive Pulmonary Disease Treatment Algorithm
8. Unmet needs
9. Chronic Obstructive Pulmonary Disease 7 Major Market Analysis
10. Chronic Obstructive Pulmonary Disease Market Outlook by Country
10.1. The United States: Market Outlook
10.2. EU-5 Countries: Market Outlook
10.2.1. Germany
10.2.2. France
10.2.3. United Kingdom
10.2.4. Spain
10.2.5. Italy
10.3. Japan: Market Outlook
11. Market Drivers
12. Market Barriers
13. Appendix
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight